Biweekly Paclitaxel Plus Bevacizumab as First Line Treatment for Older Patients With Metastatic Breast Cancer
Elderly individuals make up a large part of the breast cancer population. Older women are
more likely than younger women to be diagnosed at a more advanced stage of breast cancer.
However, when treated with chemotherapy for metastatic disease they derive similar benefits
to their younger counterparts. Preference should be given to chemotherapeutic drugs with
safer profiles regimens, such as weekly taxane, according to the SIOG recommendations.
Recently, initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab
demonstrated prolonged progression-free survival, as compared with paclitaxel alone
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall Response Rate
Objective responses confirmed by CT or MRI every 3 months
Dimitris Mavrudis, MD
University Hospital of Crete
Greece: National Organization of Medicines